morn deliv strong beat top-lin
coupl bottom-lin out-performance revenu
report beat street bottom line cash
ep street softer gm
due fx steril cost off-set lower sg
 line better tax op expens
non-op expens also help drive beat
manag reiter top-lin guidanc organ growth
rais report ep outlook prior chang
guidanc reflect beat tailwind juli debt refinanc
compani fx outlook get wors effect point
underli rais versu report rais compar
street jpme head print
updat estim establish decemb price target
forecast sale report organ
cash ep forecast sale
report organ cash ep new
price target valu share cash ep slight discount
large-cap peer group see appropri given modest near-term
headwind off-set solid longer term outlook
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
past year weve seen signific turnaround
perform manag return
consist exceed expect importantli
materi improv gener
stick point mani investor next month
believ medtron grow least plu see
number underappreci data present
transform new product launch appear
fulli appreci street conserv leav
potenti catalyst see come upsid vs
forecast manag set appropri
conserv bar long-rang top-lin earn
progress june analyst day see meaning
upsid street estim year ahead potenti
multipl expans sustain execut
dec price target share
base price-to-earnings multipl slight discount
large-cap med-tech peer set appli calendar ep
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
invest thesi valuat risk
past year weve seen signific turnaround perform
manag deliv four consecut beat-and-rais quarter
top- bottom-lin out-performance return consist exceed
expect importantli materi improv gener
stick point mani investor next month believ
grow least plu see number underappreci data
present transform new product launch appear fulli
appreci street conserv leav potenti catalyst
see come upsid vs forecast manag set appropri
conserv bar long-rang top-lin earn progress june
analyst day see meaning upsid street estim year ahead
potenti multipl expans sustain execut
dec price target share base price-to-earnings multipl
slight discount large-cap med-tech peer set appli calendar
ep estim see appropri given compani in-lin outlook
long-term off-set modest headwind near-term
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower-than-anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover applic also certifi per kofia requir analysi made
good faith view reflect opinion without undu influenc intervent
